Orexin Agonist TAK-861 Shows Pronounced Effects in Phase 2b Trial of Narcolepsy Type 1

Published Date: 20 Jun 2024

Across both the primary and secondary end points, treatment with TAK-861 resulted in significant improvements in symptom severity among patients with narcolepsy type 1.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Q&A: When will individuals be able to receive customized cancer vaccines?

2.

Canadian Group Calls for Earlier Colorectal Cancer Screening

3.

Children living near oil and gas wells face higher risk of rare leukemia, studies show

4.

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.

5.

Talquetamab Combos Show Survival Benefit in r/r Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot